

A is a bond or independently selected

from -O-, -S-, -N(R⁵)-, -C(O)N(R⁵)-, -N(R⁵)C(O)-, -S(O)₂N(R⁵)-, -N(R⁵)S(O)₂-, -S(O)(=N R⁵)-N(R⁵)-, -N(R⁵)(NR⁵=)


S(O)-, -S(=NR⁵)₂-N(R⁵)-, -N(R⁵)(NR⁵=)₂S-, -C(R⁵)=C(R⁵)-, -C≡C-,

5 , -C(O)O-, -OC(O)-, -C(O)-, -S(O)-, -S(O)₂-, -S(=NR⁵)-, -S(O)(=NR⁵)-, -S(=NR⁵)₂-, -(R⁵)(O)S=N-, -(R⁵N=)(O)S-, and -N=(O)(R⁵)S-;

R⁵ is independently selected from H, C₁₋₆-alkyl- and NC-;

or a salt thereof.


In another aspect, there is provided a compound of formula **1'**



10


wherein R¹, R², R³ and R⁴ have the meaning as defined herein.

In another aspect, there is provided a compound selected from




or a pharmaceutically acceptable salt thereof.

15 In another aspect, there is provided a compound selected from




or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound selected from




or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound selected from




5 or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound selected from



or a pharmaceutically acceptable salt thereof.


In another aspect, there is provided a compound selected from



10


or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound selected from




or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound selected from



or a pharmaceutically acceptable salt thereof.


In another aspect, there is provided a compound selected from



5

or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound selected from



or a pharmaceutically acceptable salt thereof.

- 10 In another aspect, there is provided a compound of formula **1** as defined herein for use as a medicament.

- In another aspect, there is provided a compound as defined herein for use as a medicament for the treatment of asthma and allergic diseases, gastrointestinal inflammatory diseases, eosinophilic diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes, rheumatoid arthritis and atherosclerosis.

- 15 In another aspect, there is provided pharmaceutical composition, characterised in that it contains one or more compounds of formula **1** as defined herein or a pharmaceutically active salt thereof.
- In another aspect, there is provided the use of a compound of formula **1** as defined herein in the manufacture of a medicament for the treatment or prevention of a diseases in which DPPI activity inhibitors have a therapeutic benefit, wherein said disease is selected from the group
- 20

consisting of chronic obstructive pulmonary disease (COPD), emphysema and alpha1 -antitrypsin deficiency.

In another aspect, there is provided a pharmaceutical composition comprising additionally to a compound of formula **1**, as defined herein, a pharmaceutically active compound selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors,
5 LTD4-antagonists, EGFR-inhibitors, CRTH2 inhibitors, 5-LO-inhibitors, Histamine receptor antagonists, CCR9 antagonists and SYK-inhibitors, NE-inhibitors, MMP9 inhibitors, MMP12 inhibitors, but also combinations of two or three active substances.

10

DETAILED DESCRIPTION OF THE INVENTION


A compound of formula **1**

wherein the N-atom is optionally substituted with $-R^{2.2}$, wherein

- $R^{2.2}$ is independently selected from H-A- C_{1-6} -alkylene-, C_{3-8} -cycloalkyl-,
 C_{1-6} -alkyl-A- C_{1-6} -alkylene-, C_{3-8} -cycloalkyl-A- C_{1-6} -alkylene-,
 5 C_{1-6} -haloalkyl-A- C_{1-6} -alkylene-, $R^{2.1.1}$ -A- C_{1-6} -alkylene-, C_{1-6} -alkyl-S(O)₂-,
 C_{1-6} -alkyl-C(O)- and $R^{2.1.1}$ -A-;


or a salt thereof.

- 10 **14.** A compound of formula **1'**




wherein R^1 , R^2 , R^3 and R^4 have the meaning of one of the claims 1 to 12.

- 15 **15.** A compound selected from




or a pharmaceutically acceptable salt thereof.

16. A compound selected from




or a pharmaceutically acceptable salt thereof.

5 17. A compound selected from



or a pharmaceutically acceptable salt thereof.


18. A compound selected from



10


or a pharmaceutically acceptable salt thereof.

19. A compound selected from




15 or a pharmaceutically acceptable salt thereof.

20. A compound selected from




or a pharmaceutically acceptable salt thereof.

5 21. A compound selected from



or a pharmaceutically acceptable salt thereof.


22. A compound selected from



10


or a pharmaceutically acceptable salt thereof.

23. A compound selected from



15 or a pharmaceutically acceptable salt thereof.

24. A compound selected from



or a pharmaceutically acceptable salt thereof.

5 ~~1525.~~ A compound of formula **1** according to any one claims 1 to ~~13-24~~ for use as a medicament.

~~1626.~~ A compound of formula **1** according to any one claims 1 to ~~13-24~~ for use as a medicament for the treatment of asthma and allergic diseases, gastrointestinal inflammatory diseases, eosinophilic diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes,
10 rheumatoid arthritis and atherosclerosis.

~~1727.~~ Pharmaceutical composition, characterised in that it contains one or more compounds of formula **1** according to any one of claims 1 to ~~13-24~~ or a pharmaceutically active salt thereof.

15 ~~1828.~~ Use of a compound of formula **1** according to one of claims 1-~~13-24~~ in the manufacture of a medicament for the treatment or prevention of a diseases in which DPPI activity inhibitors have a therapeutic benefit, wherein said disease is selected from the group consisting of chronic obstructive pulmonary disease (COPD), emphysema and alpha1 -antitrypsin deficiency.

~~1929~~. A pharmaceutical composition comprising additionally to a compound of formula 1, according to any one of claims 1 to ~~1324~~, a pharmaceutically active compound selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, CRTH2 inhibitors, 5-LO-inhibitors, Histamine receptor antagonists, CCR9 antagonists and SYK-inhibitors, NE-inhibitors, MMP9 inhibitors, MMP12 inhibitors, but also combinations of two or three active substances.